Skip to content

Study · Non-randomized trial · n = 162 · 2021

2 results

iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial.

Yabe D, Iizuka K, Baxter M, Watanabe D, Kaneto H

Journal of diabetes investigation19 Jun 2021Cited by 5 (Europe PMC)

PMID33945227 (opens in a new tab)PMCIDPMC8565419 (opens in a new tab)DOI10.1111/jdi.13563 (opens in a new tab)PepBankPUB-33945227
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Japanese patients with baseline residual hyperglycemia, prevalence at week 26 was 15.7% with iGlarLixi versus 36.9% with insulin glargine.

    In plain wordsIn Japanese patients with residual high glucose, its prevalence was lower with added lixisenatide than insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseResidual hyperglycemia at week 26
    Study

    n = 162

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Residual hyperglycemia proportion at week 26
    15.7%
    iGlarLixi
    Residual hyperglycemia proportion at week 26
    36.9%
    iGlar

    Source sentences

    Summary
    The proportion of patients with residual hyperglycemia at week 26 decreased to 15.7% in the iGlarLixi group, and increased to 36.9% in the iGlar group.
    2 context sentences
    Summary · context
    Post-hoc analysis of the LixiLan JP-L trial (NCT02752412) compared the effect of iGlarLixi with iGlar on this specific subpopulation with residual hyperglycemia.
    Summary · context
    Outcomes at week 26 (based on the last observation carried forward) were assessed in patients in the modified intent-to-treat population with baseline residual hyperglycemia.
  2. 02HumanNon-randomized trialEfficacy outcome

    In Japanese patients with residual hyperglycemia, iGlarLixi reduced HbA1c more than insulin glargine, with a difference of -0.72% (P < 0.0001).

    In plain wordsIn Japanese patients with residual high glucose, added lixisenatide reduced HbA1c more than insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c between treatment groups
    Study

    n = 162

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c difference between groups
    −0.72%
    iGlarLixi vs iGlar, week 26
    P value
    < 0.0001
    iGlarLixi vs iGlar, week 26

    Source sentences

    Summary
    Patients in the iGlarLixi group had significantly greater reductions in glycated hemoglobin compared with the iGlar group (-0.72% difference between groups; P < 0.0001).
    2 context sentences
    Summary · context
    Post-hoc analysis of the LixiLan JP-L trial (NCT02752412) compared the effect of iGlarLixi with iGlar on this specific subpopulation with residual hyperglycemia.
    Summary · context
    Outcomes at week 26 (based on the last observation carried forward) were assessed in patients in the modified intent-to-treat population with baseline residual hyperglycemia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.